Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

BACKGROUND: We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) on ppOS. METHODS: Recursive partitioning analysis (RPA) was performed to model r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Ribas, Antoni, Larkin, James, McArthur, Grant A., Lewis, Karl D., Hauschild, Axel, Flaherty, Keith T., McKenna, Edward, Zhu, Qian, Mun, Yong, Dréno, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397682/
https://www.ncbi.nlm.nih.gov/pubmed/32746839
http://dx.doi.org/10.1186/s12967-020-02458-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397682/
https://www.ncbi.nlm.nih.gov/pubmed/32746839
http://dx.doi.org/10.1186/s12967-020-02458-x

Ejemplares similares